Eli Lilly and Company revised earnings guidance for the year 2022. For the year, the company expects revised revenue to be in the range of $28.5 billion to $29.0 billion and earnings per share to be in the range of $6.50 to $6.65 compared to previously expected revenue to be in the range of $28.8 billion to $29.3 billion and earnings per share to be in the range of $6.96 to $7.11.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
745.7 USD | +1.96% | -0.14% | +27.92% |
Apr. 23 | Global markets live: Bayer, PepsiCo, Halliburton, Spotify, Apple... | |
Apr. 23 | Alzheimer's drug adoption in US slowed by doctors' skepticism | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.92% | 672B | |
+27.22% | 570B | |
-4.59% | 360B | |
+16.38% | 321B | |
+9.39% | 300B | |
+7.45% | 217B | |
+5.87% | 199B | |
-8.47% | 204B | |
-8.58% | 149B | |
-4.99% | 147B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly and Company Revises Earnings Guidance for the Year 2022